tetano
Editor, Senior Moderator
BMC Pediatr
. 2021 Jun 8;21(1):267.
doi: 10.1186/s12887-021-02743-8.
COVID-19 related multisystem inflammatory syndrome in children (MIS-C): a case series from a tertiary care pediatric hospital in Qatar
Mohammad Rubayet Hasan[SUP] 1 2 [/SUP], Khaled Al Zubaidi[SUP] 3 [/SUP], Karim Diab[SUP] 3 [/SUP], Yahia Hejazi[SUP] 3 [/SUP], Sharon Bout-Tabaku[SUP] 3 4 [/SUP], Buthaina Al-Adba[SUP] 3 [/SUP], Eman Al Maslamani[SUP] 3 [/SUP], Mohammad Janahi[SUP] 3 [/SUP], Diane Roscoe[SUP] 3 [/SUP], Andres Perez Lopez[SUP] 3 4 [/SUP], Patrick Tang[SUP] 3 4 [/SUP]
Affiliations
Abstract
Background: Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe complication of coronavirus disease 2019 (COVID-19) in children, which is increasingly being reported worldwide. Here we report the first case series of 7 children diagnosed with MIS-C in Qatar.
Methods: Clinical features and outcomes of COVID-19 positive patients admitted to Sidra Medicine, Qatar from June to October 2020, who met the WHO case definition for MIS-C were reviewed.
Results: The mean age in our case series was 5.6 years, of which 71.4% were males. All patients were previously healthy but had a history of COVID-19 infection. Fever, rash, vomiting and abdominal pain were the most common symptoms (70-100%). The average hospitalization was 12.9 days with no case fatalities. Laboratory findings included lymphopenia and thrombocytopenia in most patients, as well as evidence of coagulopathy and elevated inflammatory markers such as C-reactive protein, ferritin and procalcitonin. Many patients (71.4%) required inotropic support in intensive care, while only one required respiratory support. Although all patients had elevated cardiac biomarkers, cardiovascular involvement was observed in 42.9% of patients with one patient developing a giant coronary aneurysm. All patients received intravenous immunoglobulin (IVIG) and 86% of patients received corticosteroids, with two patients requiring treatment with IL-1 inhibitors.
Conclusions: Our report is one of the first reports on MIS-C from Asia. Although clinical features and outcomes are not significantly different from those reported elsewhere, lack of case fatalities in our cohort may indicate that early recognition and prompt medical attention is necessary for a favorable outcome in MIS-C.
Keywords: COVID-19; Kawasaki disease; Multisystem inflammatory syndrome (MIS-C); SARS-CoV-2.
. 2021 Jun 8;21(1):267.
doi: 10.1186/s12887-021-02743-8.
COVID-19 related multisystem inflammatory syndrome in children (MIS-C): a case series from a tertiary care pediatric hospital in Qatar
Mohammad Rubayet Hasan[SUP] 1 2 [/SUP], Khaled Al Zubaidi[SUP] 3 [/SUP], Karim Diab[SUP] 3 [/SUP], Yahia Hejazi[SUP] 3 [/SUP], Sharon Bout-Tabaku[SUP] 3 4 [/SUP], Buthaina Al-Adba[SUP] 3 [/SUP], Eman Al Maslamani[SUP] 3 [/SUP], Mohammad Janahi[SUP] 3 [/SUP], Diane Roscoe[SUP] 3 [/SUP], Andres Perez Lopez[SUP] 3 4 [/SUP], Patrick Tang[SUP] 3 4 [/SUP]
Affiliations
- PMID: 34103044
- DOI: 10.1186/s12887-021-02743-8
Abstract
Background: Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe complication of coronavirus disease 2019 (COVID-19) in children, which is increasingly being reported worldwide. Here we report the first case series of 7 children diagnosed with MIS-C in Qatar.
Methods: Clinical features and outcomes of COVID-19 positive patients admitted to Sidra Medicine, Qatar from June to October 2020, who met the WHO case definition for MIS-C were reviewed.
Results: The mean age in our case series was 5.6 years, of which 71.4% were males. All patients were previously healthy but had a history of COVID-19 infection. Fever, rash, vomiting and abdominal pain were the most common symptoms (70-100%). The average hospitalization was 12.9 days with no case fatalities. Laboratory findings included lymphopenia and thrombocytopenia in most patients, as well as evidence of coagulopathy and elevated inflammatory markers such as C-reactive protein, ferritin and procalcitonin. Many patients (71.4%) required inotropic support in intensive care, while only one required respiratory support. Although all patients had elevated cardiac biomarkers, cardiovascular involvement was observed in 42.9% of patients with one patient developing a giant coronary aneurysm. All patients received intravenous immunoglobulin (IVIG) and 86% of patients received corticosteroids, with two patients requiring treatment with IL-1 inhibitors.
Conclusions: Our report is one of the first reports on MIS-C from Asia. Although clinical features and outcomes are not significantly different from those reported elsewhere, lack of case fatalities in our cohort may indicate that early recognition and prompt medical attention is necessary for a favorable outcome in MIS-C.
Keywords: COVID-19; Kawasaki disease; Multisystem inflammatory syndrome (MIS-C); SARS-CoV-2.